Cite
HARVARD Citation
Wang, J. et al. (n.d.). 164P TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter phase Ⅱ trial. Immuno-oncology technology. p. . [Online].